SCHEMBL20074802

SCHEMBL20074802

CC(C)n1cncc1-c1cc(C(=O)NC(C)(C)C)cc(-c2ccc(C(F)(F)F)cc2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY14 Q15391 3/20 0.45
CLK2 P49760 1/20 0.40
CLK3 P49761 1/20 0.40
GSK3B P49841 1/20 0.40
DYRK1A Q13627 1/20 0.40
MAP3K5 Q99683 1/20 0.39
HSP90AA1 P07900 1/20 0.39
HSP90AB1 P08238 1/20 0.39
MCHR1 Q99705 4/20 0.38
ALOX5AP P20292 2/20 0.38
FEN1 P39748 2/20 0.38
JAK2 O60674 1/20 0.38
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
PSEN1 P49768 1/20 0.37
PSEN2 P49810 1/20 0.37
APH1B Q8WW43 1/20 0.37
NCSTN Q92542 1/20 0.37
APH1A Q96BI3 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30089420 0.90 CLK2 (0.41) P2RY14CLK2CLK3GSK3BDYRK1A
SCHEMBL20074766 0.90 CLK2 (0.41) P2RY14CLK2CLK3GSK3BDYRK1A
SCHEMBL20074710 0.88 GSK3B (0.43) CLK2CLK3GSK3BDYRK1AMAP3K5
SCHEMBL20075350 0.86 P2RY14 (0.47) P2RY14CLK2CLK3GSK3BDYRK1A
SCHEMBL20074833 0.85 P2RY14 (0.46) P2RY14HSP90AA1HSP90AB1MCHR1ALOX5AP
SCHEMBL20074601 0.84 P2RY14 (0.48) P2RY14MCHR1ALOX5APFEN1ALDH1A1
SCHEMBL19642037 0.80 P2RY14 (0.48) P2RY14MCHR1ALOX5APFEN1PSEN1
SCHEMBL20074610 0.76 HTR6 (0.42) P2RY14CLK2CLK3GSK3BDYRK1A
SCHEMBL19641943 0.76 P2RY14 (0.47) P2RY14MCHR1ALOX5APFEN1JAK2
SCHEMBL20075391 0.75 GSK3B (0.51) CLK2CLK3GSK3BDYRK1AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109563049-B Imidazole compounds as EAAT3 inhibitors 豪夫迈·罗氏有限公司 2022-11-29 CN claimed
EP-3526201-B1 IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS HOFFMANN LA ROCHE (CH) 2020-11-18 EP claimed
CN-109563049-B Imidazole compounds as EAAT3 inhibitors 豪夫迈·罗氏有限公司 2022-11-29 CN disclosed
EP-3526201-B1 IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS HOFFMANN LA ROCHE (CH) 2020-11-18 EP disclosed
EP-3526201-B1 IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS HOFFMANN LA ROCHE (CH) 2020-11-18 EP disclosed
US-10556870-B2 Imidazole compounds as EAAT3 inhibitors HOFFMANN-LA ROCHE INC. (US) 2020-02-11 US disclosed
US-10556870-B2 Imidazole compounds as EAAT3 inhibitors HOFFMANN-LA ROCHE INC. (US) 2020-02-11 US disclosed
US-20190233379-A1 IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2019-08-01 US disclosed
US-20190233379-A1 IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2019-08-01 US disclosed
WO-2018069362-A1 IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10556870-B2 Imidazole compounds as EAAT3 inhibitors SLC1A1, SLC1A3, SLC1A2 P2RY14 2903/4885CLK2 2424/4885CLK3 2582/4885
US-20190233379-A1 IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS SLC1A1, SLC1A3, SLC1A2 P2RY14 2903/4885CLK2 2424/4885CLK3 2582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.